Clinical trial · Observational
Evolution of Multiple Primary Lung Cancer (Evolution)
The Genetic Evolution and Microenvironment of Multiple Primary Lung Cancer
NCT04326751CI-TRIAL-00044334unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the evolutionary genomic landscape, explore the genetic tumor heterogeneity and microenvironment of multiple primary lung cancer (MPLC) by using tissue genetic analysis and circulating tumor DNA detection, in order to provide robust evidence for the diagnosis, treatment, and surveillance of MPLC.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Multiple Primary Lung Cancers | Malignant Neoplasm of Lung - Multiple Primary Sites | ALIAS | 0.90 |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Tumor heterogeneity of multiple primary lung cancer
- timeFrame
- 3 year
- description
- Explore the intra-tumor and inter-tumor genetic heterogeneity by analysis of clonal and subclonal mutations detected by ctDNA.
- measure
- Microenvironment of multiple primary lung cancer
- timeFrame
- 3 year
- description
- Using RNA sequencing and T cell receptor (TCR) sequencing to evaluate the microenvironment of each lesion of multiple primary lung cancer, including T cell receptpr clonality ,diversity , evenness, and richness.
Secondary outcomes (2)
- measure
- Correlation between ctDNA and clonal variation
- timeFrame
- 3 year
- description
- Explore the correlation between the detection rate of ctDNA and subclonal mutations of different tumor sites detected by genetic analysis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 to 80 years 1. Patients who are clinically diagnosed multiple lung cancers, and undergo surgical treatment. 2. No history of any malignancy in recent 5 years. 3. No chemotherapy, radiotherapy or targeted therapy will be performed before surgery. 4. Surgical removal of at least 2 tumors confirmed to be lung cancer postoperatively by pathologic evaluation. Exclusion Criteria: 1. All lesions present as pure ground-glass opacities (GGOs) on CT scans. 2. Patients who do not undergo R0 resection (including tumors located bilaterally but only unilaterally resected). 3. Unqualified blood samples. 4. Unable to comply with the study procedure
References
Publications (0)
Data not yet available
No reference posted for this study.